Novartis antibiotic retreat doesn’t stop Sandoz buying GSK d...
Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalospor